Literature DB >> 20233110

Epidemiology of multiple sclerosis in Europe: a review.

Ephrosyni Koutsouraki1, Vassiliki Costa, Stavros Baloyannis.   

Abstract

Multiple sclerosis (MS) is a progressive demyelinating and degenerative disease of the CNS with symptoms dependent on the type of the disease and the site of lesions. During the progression of the disease, symptoms become more permanent and progressive disability ensues. MS is a disease characterized by wide variations between patients, thus making categorization difficult. The aim of the current study was to review the existing epidemiological data of MS in Europe published during the last decade (2000-2009), using PubMed. Findings revealed an increasing incidence of MS during the last decade. Recent data indicate that latitude does not play a key role in determining the onset of the disease. MS has a significant impact on the quality of life for most patients over many years. The disease is twice as common in women than in men, and is at its peak in the most economically productive years of life. Pregnancy, postpartum status and vaccines may influence the onset and the course of the disease. Only one of the reviewed papers provides a view of progression from onset to death.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233110     DOI: 10.3109/09540261003589216

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  27 in total

1.  Reactivated astrocytes as a possible source of oligodendrocyte precursors for remyelination in remitting phase of experimental autoimmune encephalomyelitis rats.

Authors:  An-Chen Guo; Takho Chu; Xu-Qing Liu; Huan-Xing Su; Wu-Tian Wu
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

2.  Anti-FcεR1 antibody injections activate basophils and mast cells and delay Type 1 diabetes onset in NOD mice.

Authors:  Marc P Hübner; David Larson; Marina N Torrero; Ellen Mueller; Yinghui Shi; Kristin E Killoran; Edward Mitre
Journal:  Clin Immunol       Date:  2011-08-23       Impact factor: 3.969

Review 3.  [Neuro-urological dysfunction of the lower urinary tract in CNS diseases: pathophysiology, epidemiology, and treatment options].

Authors:  U Mehnert; M Nehiba
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

Review 4.  Neurogenic bowel dysfunction in patients with spinal cord injury, myelomeningocele, multiple sclerosis and Parkinson's disease.

Authors:  Richard A Awad
Journal:  World J Gastroenterol       Date:  2011-12-14       Impact factor: 5.742

5.  Prevalence of Multiple Sclerosis in the Middle Black Sea Region of Turkey and Demographic Characteristics of Patients.

Authors:  Neslihan Akdemir; Murat Terzi; Nilden Arslan; Musa Onar
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

6.  Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997-2008.

Authors:  Ching-Piao Tsai; Charles Tzu-Chi Lee
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

7.  Impact of Proactive Case Management by Multiple Sclerosis Specialist Nurses on Use of Unscheduled Care and Emergency Presentation in Multiple Sclerosis: A Case Study.

Authors:  Alison Leary; Debbie Quinn; Amy Bowen
Journal:  Int J MS Care       Date:  2015 Jul-Aug

8.  Fatigue, Sleep Quality, and Disability in Relation to Quality of Life in Multiple Sclerosis.

Authors:  Fatemeh Moghaddam Tabrizi; Moloud Radfar
Journal:  Int J MS Care       Date:  2015 Nov-Dec

9.  Multiple sclerosis in Japan appears to be a milder disease compared to the UK.

Authors:  L Piccolo; G Kumar; I Nakashima; T Misu; Y Kong; B Wakerley; S Ryan; A Cavey; K Fujihara; Jacqueline Palace
Journal:  J Neurol       Date:  2015-01-22       Impact factor: 4.849

10.  Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy.

Authors:  Nadja Borisow; Andrea Döring; Caspar F Pfueller; Friedemann Paul; Jan Dörr; Kerstin Hellwig
Journal:  EPMA J       Date:  2012-06-22       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.